Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + mFOLFOX-6 induction therapy before surgery in quadruple wild-type intermediate-risk rectal cancer
2016-002333-29Phase 2Terminated
- Sponsor
- GEMCAD
- Start
- Feb 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, fluorouracil, folinic acid and oxaliplatin in rectal adenocarcinoma and colorectal cancer (CRC), sponsored by GEMCAD. Primary endpoint: Pathologic complete response. Started Feb 2017; status: terminated.
02
Drugs
panitumumabfluorouracilfolinic acidoxaliplatin
03
Conditions
rectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2016-002333-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002333-29.